Skip to main content

Table 3 Summary of cohort characteristics and clinical follow up for conventionally fractionated and hypofractionated datasets

From: Challenges in radiobiological modeling: can we decide between LQ and LQ-L models based on reviewed clinical NSCLC treatment outcome data?

Dataset Total No. pats. % T1 Histology % histology unknown % inoperable Median age (range) [y] Median follow-up (range) [m] Median BED10@isoc (range) [Gy] Median No. Pats (range)
    % Adeno % SCC % NOS % Other       
CF 344 48.0 % 26.3 47.0 15.5 11.2 11.6 86.3 72 (35–90) 28.5 (2–216) 82.0 (67.2-93.5) 43 (31–56)
HF 1975 66.3 % 50.4 31.1 13.5 5.0 35.9 55.2 75 (29–94) 27 (0.3–115) 119.6 (76.8–347.5) 57 (25–177)
Total 2319 63.6 % 45.8 34.1 13.9 6.2 31.9 59.8 74 (29–94) 27 (0.3–216) 105.6 (67.2–347.5) 53 (25–177)
  1. Adeno adenocarcinoma, SCC squamous cell carcinoma, NOS carcinoma not otherwise specified, HF hypofractionated treatment regime, CF conventionally fractionated treatment schedule